TRex Bio (TRXB) director Joel S. Marcus holds preferred shares that will convert immediately before its IPO closes.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
TRex Bio director Joel S. Marcus holds 161,828 shares of Series B Convertible Preferred Stock, which will convert into common stock on a 3.8649-for-1 basis immediately prior to the company's initial public offering (IPO). This information comes from a Form 3 filing on October 8, 2026, indicating a significant pre-IPO conversion for a key insider.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.